Investigation of the added value of CT-based radiomics in predicting the development of brain metastases in patients with radically treated stage III NSCLC.

Autor:	Keek SA; The D-Lab, Department of Precision Medicine, GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Kayan E; The D-Lab, Department of Precision Medicine, GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Chatterjee A; The D-Lab, Department of Precision Medicine, GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Belderbos JSA; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bootsma G; Department of Pulmonary Diseases, Zuyderland Hospital, Heerlen, The Netherlands., van den Borne B; Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, The Netherlands., Dingemans AC; Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands., Gietema HA; Department of Radiology and Nuclear Medicine, GROW - School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands., Groen HJM; Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Herder J; Department of Pulmonary Diseases, Meander Medical Center, Amersfoort, The Netherlands., Pitz C; Department of Pulmonary Diseases, Laurentius Hospital, Roermond, The Netherlands., Praag J; Department of Radiotherapy, Erasmus MC, Rotterdam, The Netherlands., De Ruysscher D; Department of Radiation Oncology (Maastro), GROW - School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands., Schoenmaekers J; Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands., Smit HJM; Department of Pulmonary Diseases, Rijnstate, Arnhem, The Netherlands., Stigt J; Department of Pulmonary Diseases, Isala Hospital, Zwolle, The Netherlands., Westenend M; Department of Pulmonary Diseases, VieCuri, Venlo, The Netherlands., Zeng H; Department of Radiation Oncology (Maastro), GROW - School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, The Netherlands., Woodruff HC; The D-Lab, Department of Precision Medicine, GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Lambin P; The D-Lab, Department of Precision Medicine, GROW - School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Hendriks L; Department of Pulmonary Diseases, GROW - School for Oncology and Reproduction, Maastricht University Medical Centre+, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
Jazyk:	angličtina
Zdroj:	Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2022 Aug 22; Vol. 14, pp. 17588359221116605. Date of Electronic Publication: 2022 Aug 22 (Print Publication: 2022).
DOI:	10.1177/17588359221116605
Abstrakt:	Introduction: Despite radical intent therapy for patients with stage III non-small-cell lung cancer (NSCLC), cumulative incidence of brain metastases (BM) reaches 30%. Current risk stratification methods fail to accurately identify these patients. As radiomics features have been shown to have predictive value, this study aims to develop a model combining clinical risk factors with radiomics features for BM development in patients with radically treated stage III NSCLC. Methods: Retrospective analysis of two prospective multicentre studies. Inclusion criteria: adequately staged [ 18 F-fluorodeoxyglucose positron emission tomography-computed tomography (18-FDG-PET-CT), contrast-enhanced chest CT, contrast-enhanced brain magnetic resonance imaging/CT] and radically treated stage III NSCLC, exclusion criteria: second primary within 2 years of NSCLC diagnosis and prior prophylactic cranial irradiation. Primary endpoint was BM development any time during follow-up (FU). CT-based radiomics features ( N  = 530) were extracted from the primary lung tumour on 18-FDG-PET-CT images, and a list of clinical features ( N  = 8) was collected. Univariate feature selection based on the area under the curve (AUC) of the receiver operating characteristic was performed to identify relevant features. Generalized linear models were trained using the selected features, and multivariate predictive performance was assessed through the AUC. Results: In total, 219 patients were eligible for analysis. Median FU was 59.4 months for the training cohort and 67.3 months for the validation cohort; 21 (15%) and 17 (22%) patients developed BM in the training and validation cohort, respectively. Two relevant clinical features (age and adenocarcinoma histology) and four relevant radiomics features were identified as predictive. The clinical model yielded the highest AUC value of 0.71 (95% CI: 0.58-0.84), better than radiomics or a combination of clinical parameters and radiomics (both an AUC of 0.62, 95% CIs of 0.47-076 and 0.48-0.76, respectively). Conclusion: CT-based radiomics features of primary NSCLC in the current setup could not improve on a model based on clinical predictors (age and adenocarcinoma histology) of BM development in radically treated stage III NSCLC patients. Competing Interests: Competing interests: P.L. reports, within and outside the submitted work, grants/sponsored research agreements from Radiomics SA, ptTheragnostic/DNAmito, Health Innovation Ventures. He received an advisor/presenter fee and/or reimbursement of travel costs/consultancy fee and/or in kind manpower contribution from Radiomics SA, BHV, Merck, Varian, Elekta, ptTheragnostic, BMS, and Convert pharmaceuticals. Dr Lambin has minority shares in the company Radiomics SA, Convert pharmaceuticals, Comunicare Solutions, and LivingMed Biotech, he is a co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Radiomics SA and one issued patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, one non-issued patent on LSRT (PCT/ P126537PC00) licensed to Varian Medical, three non-patented invention (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures and three non-issues, non-licensed patents on Deep & handcrafted Radiomics (US P125078US00, PCT/NL/2020/050794, n° N2028271). He confirms that none of the above entities or funding was involved in the preparation of this paper. LH: none related to current manuscript, outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim, AstraZeneca (all institution, furthermore Takeda and Beigene in negotiation [institution]); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech, Bayer (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD /Merck, GSK, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati. DdR: none related to current manuscript, outside of current manuscript: grants from BMS, AstraZeneca, Seat tle Genetics, Philips, Olink, BeiGene. Advisory board (no personal fees: AstraZeneca, Philips. HW: has minority shares in the company Radiomics SA. H.G: Advisory board (no personal fees): Roche, Astra-Zeneca, Boehringer-Ingelheim, Lilly, Novartis. (© The Author(s), 2022.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu